BioSpace News Archive

Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May.

TherapeuticsMD Announces Poster Presentation of ANNOVERA ® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting -Poster included analyses of ANNOVERA Phase 3 menstrual bleeding profile data-

Amcyte Pharma, a Seattle-based company dedicated to the commercialization of immunomodulators, announced the results of an independent clinical trial among ICU staff suggesting that its product, NasitrolTM nasal spray, represents a safe and effective treatment that could prevent transmission of COVID-19.

AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease Anticipates initiating registration trial with kidney biopsy endpoint in mid-2022 to support potential full approval of AVR-RD-01 as first-line therapy, subject to FDA discussion and agreement Two additional patients dosed in last two months in ongoing FAB-GT Phase 2 trial; plan to enroll a total of up to 14 participants

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay. More than one million Vectra tests have been comp

Positioned as Leader in Emerging Psychedelic Therapeutics Market through Robust IP Portfolio, Novel Clinical Trials and Evolving Proprietary Technology

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, announced the appointment of Peter Senior to Director of Business Development.

Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of Christine Silverstein as Chief Financial Officer.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that the Company will ring the NASDAQ closing bell on Wednesday, May 5, 2021, to highlight May as Mental Health Awareness Month.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity, reported financial results and provided a business update for the first quarter ended March 31, 2021.